Chronic Myelogenous Leukemia (CML) is a hematopoietic stem cell disorder characterized by the philadelphia Chormosome, the result of a (9:22) Translocation that fuses the BCR Gene with the ABL1 Gene and produces the constitutively active BCR-ABL1 Tryosine Kinase. Imatinib mesylate (STI571:Gleevec), A BCR-ABL Tyrosine Kinase inhibitor is highly effective in treating the early stages of CML. of patients treated in chronic phase, 95% achieved a complete hematologic remission and 60% achieve a major cytogenetic response. However, the most patients in blast crisis either fail to respond or quickly relapse following an initial response to Imatinib. Alternatively spliced BCR-ABL1 MRNA with 35- nucleotide (NT) insertion is found in CML patients who show resistance to imatinib. The level of resistance may correlate with levels of expression the 35-NT Transcript.
No special preparation is needed for BCR ABL Mutation Analysis. Inform your doctor if you are on any medications or have any underlying medical conditions or allergies before undergoing BCR ABL Mutation Analysis. Your doctor depending on your condition will give specific instructions.
|UNISEX||All age groups||BCR-ABL fusion seen in CML|